Education
About Us
Working with TipRanks
Follow Us
Qualigen Therapeutics Inc (QLGN)
NASDAQ:QLGN
RESEARCH TOOLSreports
QLGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.85 - $14.99
Previous CloseN/A
Volume8.82K
Average Volume (3M)1.62M
Market Cap
$6.43M
Enterprise Value$1.42M
Total Cash (Recent Filing)$1.17M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.34
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-55.30
Shares Outstanding1,635,475
10 Day Avg. Volume4,832,624
30 Day Avg. Volume1,618,118
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-0.41
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue0.08
Enterprise Value/Gross Profit-1.27
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Qualigen Therapeutics News
PremiumCompany Announcements
Qualigen Therapeutics Secures Global Patents for QN-302
PremiumCompany Announcements
Qualigen Therapeutics Appoints New Audit Committee Chair
PremiumCompany Announcements
Qualigen Therapeutics Faces Nasdaq Delisting Notification
PremiumCompany Announcements
Qualigen Therapeutics Faces Nasdaq Delisting Threat
PremiumCompany Announcements
Qualigen Therapeutics Delays Yearly Financial ReportOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.27% Mutual Funds
1.05% Other Institutional Investors
98.62% Public Companies and Individual Investors
QLGN FAQ
What was Qualigen Therapeutics Inc’s price range in the past 12 months?
Qualigen Therapeutics Inc lowest stock price was $2.85 and its highest was $14.99 in the past 12 months.
What is Qualigen Therapeutics Inc’s market cap?
Qualigen Therapeutics Inc’s market cap is $6.43M.
When is Qualigen Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Qualigen Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Qualigen Therapeutics Inc overvalued?
According to Wall Street analysts Qualigen Therapeutics Inc’s price is currently Overvalued.
Does Qualigen Therapeutics Inc pay dividends?
Qualigen Therapeutics Inc does not currently pay dividends.
What is Qualigen Therapeutics Inc’s EPS estimate?
Qualigen Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qualigen Therapeutics Inc have?
Qualigen Therapeutics Inc has 1,635,475 shares outstanding.
What happened to Qualigen Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Qualigen Therapeutics Inc?
Currently, no hedge funds are holding shares in QLGN
Company Description
Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Technical Analysis
Quoin Pharmaceuticals
―
Aptevo Therapeutics
―
CNS Pharmaceuticals
―
Galecto
―
Tao Synergies
―